Aviva PLC I Mab Transaction History

Aviva PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$8.27 - $18.43 $143,898 - $320,682	-17,400 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$12.54 - $46.93 $33,858 - $126,711	2,700 Added 18.37%	17,400 $283,000
Q4 2021 Feb 10, 2022	BUY	$45.28 - $74.5 $135,840 - $223,500	3,000 Added 25.64%	14,700 $697,000
Q3 2021 Nov 12, 2021	BUY	$57.18 - $84.43 $120,078 - $177,303	2,100 Added 21.88%	11,700 $848,000
Q2 2021 Aug 10, 2021	BUY	$47.86 - $83.95 $459,456 - $805,920	9,600 New	9,600 $806,000

16M

11.9K

3.5K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $139M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

Stay updated on Aviva PLC with notifications on news.